Willingsford – a small British company – is to receive government support to develop its innovative wound treatment which can accelerate the early stages of healing in humans and animals by 50%.
The small Southampton-based medical device company, has been awarded a £250,000 grant by the government-backed Technology Strategy Board. The money will support the development of the company’s wound healing product, Sertasil.
Sertasil assists the body in the cleaning of the wound surface, allowing the body to return to a healthy and optimal wound healing process. A clinical study involving more than 260 patients showed that Sertasil accelerated the early phases of wound healing by 50% for wounds and burns, leading to faster wound closure.
Subsequent studies have shown that SertaSil – a power that does not require extensive secondary dressings – has similar effects in dogs and horses. It has been used to treat conditions such as leg wounds in horses successfully.
Dr Frank Sams-Dodd, chief executive of Willingsford, said the award was a “fabulous endorsement” of a product that had “tremendous potential, both in the veterinary market and for use by healthcare professionals”.